WARNING

Elranatamab-bcmm is a monoclonal antibody used in the treatment of multiple myeloma, a type of blood cancer. Like any medication, it carries certain risks and potential side effects. Some common risks associated with Elranatamab-bcmm may include:

• Infusion reactions: Patients may experience infusion-related reactions during or shortly after receiving the medication, such as fever, chills, nausea, vomiting, or allergic reactions.
• Infections: Elranatamab-bcmm may increase the risk of infections, including bacterial, viral, or fungal infections. Patients should be monitored for signs of infection and treated promptly if one occurs.
• Hematologic toxicity: This medication can affect blood cell counts, including red blood cells, white blood cells, and platelets, which may increase the risk of anemia, neutropenia, or thrombocytopenia.
• Neurotoxicity: Some patients may experience neurological side effects, such as peripheral neuropathy, which can cause tingling, numbness, or weakness in the extremities.
• Tumor lysis syndrome: In some cases, the rapid destruction of cancer cells caused by Elranatamab-bcmm may lead to tumor lysis syndrome, characterized by metabolic abnormalities and organ dysfunction.
• Hepatotoxicity: Liver function abnormalities, including elevated liver enzymes, may occur with the use of Elranatamab-bcmm.
• Other side effects: Additional side effects may include fatigue, diarrhea, constipation, decreased appetite, muscle spasms, and respiratory tract infections.

It’s important for patients receiving Elranatamab-bcmm to be closely monitored by their healthcare providers for any signs of adverse reactions or complications. The benefits of treatment should be weighed against the potential risks, and patients should discuss any concerns with their healthcare team.

Why is this medication prescribed?

Elranatamab-bcmm is prescribed for the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. It is specifically indicated for use in adult patients who have received at least three prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

How should this medicine be used?

As for how Elranatamab-bcmm should be used, it is typically administered by a healthcare professional through intravenous (IV) infusion. The recommended dosage and administration schedule may vary based on individual patient factors, so it’s important for patients to follow their healthcare provider’s instructions carefully.

The infusion rate and duration may also vary based on the patient’s tolerance and any potential infusion reactions. Patients should be monitored closely during and after the infusion for any signs of adverse reactions.

Additionally, patients may receive pre-medications such as antihistamines and corticosteroids to help reduce the risk of infusion-related reactions.

Overall, the usage of Elranatamab-bcmm should be supervised by a healthcare professional experienced in the administration of anticancer therapies, and patients should communicate any concerns or side effects with their healthcare team.

Other uses for this medicine

Elranatamab-bcmm (also known as Teclistamab) is primarily used for the treatment of multiple myeloma and is not approved for other uses. It is a monoclonal antibody therapy specifically designed to target BCMA (B-cell maturation antigen), which is highly expressed on the surface of multiple myeloma cells.

What special precautions should I follow?

Regarding special precautions for Elranatamab-bcmm, patients and healthcare providers should consider the following:

• Infusion reactions: Due to the possibility of infusion-related reactions, patients should be closely monitored during and after infusion. Pre-medications may be administered to reduce the risk of reactions.
• Infections: Elranatamab-bcmm treatment may increase susceptibility to infections. Patients should be monitored for signs of infection, and prophylactic antibiotics or antiviral medications may be prescribed.
• Hematologic toxicity: Regular monitoring of blood cell counts is essential due to the potential for anemia, neutropenia, and thrombocytopenia. Dose adjustments or treatment interruptions may be necessary based on blood count results.
• Neurotoxicity: Patients should be monitored for symptoms of peripheral neuropathy, such as numbness, tingling, or weakness in the extremities. Dose modifications or treatment discontinuation may be required if neurotoxicity occurs.
• Tumor lysis syndrome: Monitoring for signs of tumor lysis syndrome, such as electrolyte imbalances and kidney dysfunction, is important, especially during the initial treatment phase.
• Hepatotoxicity: Liver function tests should be performed regularly during treatment to monitor for hepatotoxicity. Treatment may need to be adjusted or discontinued if liver enzyme elevations occur.
• Pregnancy and breastfeeding: Elranatamab-bcmm may cause fetal harm if used during pregnancy. Patients should use effective contraception during treatment and for a period after discontinuation. Breastfeeding should be avoided while receiving Elranatamab-bcmm.
• Interactions: Patients should inform their healthcare providers about all medications, supplements, and herbal products they are taking, as these may interact with Elranatamab-bcmm.

It’s crucial for patients to follow their healthcare provider’s instructions closely and report any concerning symptoms or side effects promptly. Only a qualified healthcare professional can provide personalized advice and recommendations regarding the use of Elranatamab-bcmm.

What special dietary instructions should I follow?

Regarding special dietary instructions for Elranatamab-bcmm, there are typically no specific dietary restrictions associated with its use. However, it’s essential to maintain a balanced and nutritious diet to support overall health and well-being during treatment.

What should I do if I forget a dose?

If you forget a dose of Elranatamab-bcmm, contact your healthcare provider or treatment center as soon as possible for guidance. They will advise you on the appropriate steps to take, which may include rescheduling the missed dose or adjusting your treatment schedule. It’s essential not to double up on doses unless instructed to do so by your healthcare provider. Consistency in treatment is crucial for optimal outcomes, so strive to adhere to your prescribed dosing schedule as closely as possible.

What side effects can this medication cause?

Elranatamab-bcmm, like any medication, can cause side effects, although not everyone will experience them. Some common side effects associated with Elranatamab-bcmm may include:

• Infusion reactions: Symptoms may include fever, chills, nausea, vomiting, headache, or allergic reactions. These reactions typically occur during or shortly after the infusion and are usually managed by healthcare providers.
• Infections: Elranatamab-bcmm may increase the risk of infections, such as respiratory tract infections, urinary tract infections, or fungal infections. Patients should watch for signs of infection and promptly report any symptoms to their healthcare provider.
• Hematologic toxicity: This medication can affect blood cell counts, leading to anemia (low red blood cells), neutropenia (low white blood cells), or thrombocytopenia (low platelets). Symptoms may include fatigue, weakness, increased susceptibility to infections, or easy bruising or bleeding.
• Neurological effects: Some patients may experience peripheral neuropathy, characterized by numbness, tingling, or weakness in the hands and feet. This side effect is usually temporary and may improve after treatment discontinuation or dose adjustment.
• Tumor lysis syndrome: Rapid destruction of cancer cells may lead to tumor lysis syndrome, characterized by metabolic abnormalities such as elevated potassium, phosphorus, and uric acid levels in the blood. Symptoms may include muscle cramps, nausea, vomiting, or kidney dysfunction.
• Hepatotoxicity: Elranatamab-bcmm can cause liver function abnormalities, including elevated liver enzymes. Symptoms may include jaundice (yellowing of the skin or eyes), abdominal pain, or dark urine.
• Other side effects: Additional side effects may include fatigue, diarrhea, constipation, decreased appetite, muscle spasms, cough, or respiratory tract infections.

It’s important for patients to communicate any side effects or concerns with their healthcare provider. Depending on the severity of side effects, dose adjustments, supportive care, or treatment modifications may be recommended to manage symptoms and optimize treatment outcomes.

What should I know about storage and disposal of this medication?

Storage and disposal of Elranatamab-bcmm:

• Storage: Elranatamab-bcmm should be stored in the refrigerator between 2°C to 8°C (36°F to 46°F) in the original carton to protect it from light. Do not freeze. Keep the medication away from children and pets.
• Disposal: Any unused or expired Elranatamab-bcmm should be disposed of properly according to local regulations or guidelines. Your healthcare provider or pharmacist can provide guidance on safe disposal methods.

In case of emergency/overdose

In case of emergency/overdose of Elranatamab-bcmm:

• Seek medical attention: If you suspect an overdose or experience severe adverse reactions, such as severe infusion reactions or symptoms of toxicity, seek immediate medical attention or contact your local poison control center.
• Supportive care: Treatment for overdose or severe adverse reactions will be supportive and may include measures to manage symptoms, such as providing fluids, supportive medications, or other interventions as necessary.

What other information should I know?

• Pregnancy and breastfeeding: Elranatamab-bcmm may cause harm to a developing fetus, so it is essential to use effective contraception during treatment and for a period after discontinuation. Breastfeeding should be avoided while receiving Elranatamab-bcmm.
• Monitoring: Regular monitoring by healthcare providers is necessary during treatment with Elranatamab-bcmm to assess treatment response, monitor for adverse reactions, and adjust treatment as needed.
• Interactions: Inform your healthcare provider about all medications, supplements, and herbal products you are taking, as they may interact with Elranatamab-bcmm.
• Follow-up: Attend all scheduled appointments with your healthcare provider for continued monitoring and follow-up care during and after treatment with Elranatamab-bcmm.
• Patient assistance programs: Some pharmaceutical companies offer patient assistance programs to help with access to medications or financial assistance for eligible patients. You can inquire with your healthcare provider or the medication manufacturer for more information.